Caspofungin, an antifungal agent that acts on the cell wall by inhibiting β-1, 3-glucan
synthesis, is likely to be effective for treating Pneumocystis pneumonia, because one of the …

Pneumocystis pneumonia (PCP) is one of the most critical and life-threatening infections in
immunocompromised patients with AIDS (especially CD4+ T cell less than 0.2× 109/L) …

Objectives The aim of this study was to investigate the efficacy of combination therapy of
caspofungin and TMP/SMZ (trimethoprim/sulfamethoxazole) in moderate to severe …

Background. Pneumocystis jiroveci pneumonia may be a life-threatening opportunistic
infection in immunosuppressed solid organ transplant recipients. Despite effective treatment …

Pneumocystis pneumonia (PCP) is a well-known complication in AIDS patients, but it is also
frequently diagnosed in hemato-oncological patients [1]. High-dose cotrimoxazole is the first …

Background Pneumocystis jirovecii is responsible for Pneumocystis pneumonia (PCP),
which occurs almost exclusively in immunocompromised individuals. Trimethoprim …

Echinocandins are a novel class of antifungal drugs that target β (1, 3)-D-glucan synthesis.
Animal studies have shown that these agents have activity against Pneumocystis jiroveci …

Caspofungin was used for the first time with trimethoprim/sulfamethoxazole (TMP/SMX) for
treatment of high risk Pneumocystis jiroveci pneumonia (PCP) in a pediatric …

A patient with Wegener's granulomatosis was on steroids (20 mg prednisolone per day)
when he fell ill with an atypical pneumonia caused by Pneumocystis, which was diagnosed …

Caspofungin is an echinocandin which is widely used as the first-line treatment of systemic
candidiasis (2). This drug is a noncompetitive inhibitor of the subunit GSC1 of the enzymatic …